Nab-paclitaxel Plus Carboplatin Versus Nab-paclitaxel Plus Epirubicin in the Neoadjuvant Therapy for Breast Cancer

Inclusion Criteria:

1. Females with age between 18 to 70 years old;

2. Histologically confirmed primary invasive breast cancer;

3. Histologically confirmed triple negative breast cancer;

4. Patients who planned to accept preoperative neoadjuvant therapy and had a mass largerthan 2 cm.

5. Blood specimens and 5 sections of tumor tissue at baseline, blood specimens at surgerycan be obtained.

6. Have at least one measurable lesion as per the RECIST criteria (version 1.1);

7. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal toone;

8. LVEF≥55%；

9. Bone marrow function：neutrophils (≥1.5×10^9/L), platelets (≥100×10^9/L), hemoglobin (≥90 g/L);

10. Renal and hepatic function: Serum creatinine≤ 1.5×institutional upper limit of normal (ULN); AST and ALT ≤ 2.5 × ULN; Total bilirubin≤1.5×ULN, or patients with Gilbert'ssyndrome ≤ 2.5 × ULN;

11. Patients had good compliance with the planned treatment, understood the researchprocess and written informed consent.

Exclusion Criteria:

1. Previous treatment with any cytotoxic chemotherapy, endocrine therapy, biotherapy orradiotherapy;

2. Patients with heart disease above grade II (including grade II) identified by New YorkHeart Association (NYHA) scores;

3. Patients with severe systemic infection or other serious diseases;

4. Patients allergic to or intolerant of chemotherapeutic drugs or their adjuvants;

5. Patients with other malignant tumors in the past five years, except for cured cervicalcarcinoma in situ and non-melanoma skin cancer;

6. Pregnancy or lactation, as well as reproductive age patients who refused to takeappropriate contraceptive measures in the trial;

7. Participation in any trial drug treatment or another interventional clinical trial 30days before first dose was given;

8. The researchers considered the patients who were not suitable for enrollment.